Short Interest in TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Declines By 19.5%

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) saw a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 69,700 shares, a decline of 19.5% from the March 31st total of 86,600 shares. Based on an average daily volume of 31,200 shares, the days-to-cover ratio is presently 2.2 days. Currently, 2.8% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, Roth Mkm lowered their price objective on TFF Pharmaceuticals from $56.00 to $44.00 and set a “buy” rating for the company in a report on Thursday, March 28th.

TFF Pharmaceuticals Price Performance

Shares of NASDAQ TFFP traded down $0.21 during midday trading on Monday, reaching $2.71. 43,157 shares of the company traded hands, compared to its average volume of 28,506. The company has a market cap of $6.83 million, a price-to-earnings ratio of -0.22 and a beta of 1.29. The stock has a 50-day moving average price of $5.86 and a 200 day moving average price of $6.61. TFF Pharmaceuticals has a 52 week low of $2.51 and a 52 week high of $21.25.

TFF Pharmaceuticals (NASDAQ:TFFP) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.00) by ($0.01). TFF Pharmaceuticals had a negative net margin of 2,897.95% and a negative return on equity of 163.14%. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.20 million. As a group, analysts expect that TFF Pharmaceuticals will post -7.28 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Westside Investment Management Inc. boosted its position in TFF Pharmaceuticals by 382.1% during the 1st quarter. Westside Investment Management Inc. now owns 39,225 shares of the company’s stock worth $237,000 after acquiring an additional 31,089 shares during the period. Worth Venture Partners LLC grew its position in TFF Pharmaceuticals by 66.2% during the third quarter. Worth Venture Partners LLC now owns 646,832 shares of the company’s stock valued at $226,000 after purchasing an additional 257,722 shares in the last quarter. Finally, AIGH Capital Management LLC lifted its position in TFF Pharmaceuticals by 70.7% in the 3rd quarter. AIGH Capital Management LLC now owns 2,655,235 shares of the company’s stock worth $929,000 after buying an additional 1,099,709 shares in the last quarter. 15.25% of the stock is owned by hedge funds and other institutional investors.

TFF Pharmaceuticals Company Profile

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.